The 12th Invest in ME Research Conference June, 2017, Part 2
MEMum presents the second article in a series of three about the recent 12th Invest In ME International Conference (IIMEC12) in London.
Discuss the article on the Forums.

Ruxolitinib (JAK1 JAK2 inhibitor): remarking results on intestinal inflammation

Discussion in 'Other Health News and Research' started by Aubry, Nov 2, 2017.

  1. Aubry

    Aubry Senior Member

    Messages:
    105
    Likes:
    133
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854652/#!po=31.3333

    C respresents inflamed dentric cells of the gut before and after administration of Ruxolitinib (the purple grapes are inflamed cells). This is causing probably the abnormalities seen in the micro biome of all ME/CFS patients.Since the micro biome is more and more investigated this could be very interesting for ME/CFS as well. Prof. Meirleir will start trials in 2018 with Filgotinib (another JAK inhibitor) in his patient groups.


    Skin and intestinal GvHD responds to ruxolitinib
    [​IMG]
     

    Attached Files:

    • C.jpg
      C.jpg
      File size:
      72.7 KB
      Views:
      1
    unicorn7, ErdemX, JadeD and 3 others like this.
  2. knackers323

    knackers323 Senior Member

    Messages:
    1,309
    Likes:
    367
    This looks good. Following
     
  3. jaybee00

    jaybee00

    Messages:
    80
    Likes:
    94

See more popular forum discussions.

Share This Page